Why the study?
Potassium-binding drugs have yet to prove a causal association with improved patient prognosis before widespread use can be recommended.
Do potassium binders improve prognosis in heart failure patients by allowing maintenance of guideline-directed medical therapy?
Do potassium binders improve prognosis in heart failure patients by allowing maintenance of guideline-directed medical therapy?
While potassium binders may allow maintenance of beneficial medications in heart failure, their causal association with improved prognosis remains to be proven.
Does not support routine potassium binder use for RAASi optimization; leaves open need for outcome trials to confirm prognostic benefit.
New therapeutic options to treat hyperkalaemia, such as potassium binders, have been suggested as potentially beneficial by allowing the maintenance (or increase) of the dose of medications that improve outcomes in several cardiovascular conditions, but which have in common the propensity for raising serum potassium. However, potassium binding drugs have yet to prove their causal association with improvements in patients' prognosis before their widespread use can be recommended. In this review we provided an up-to-dare appraisal on potassium binders, their potential clinical applications and directions for future research.
No takes yet. Share an insight, caveat, or question.
Zannad et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: